ALNYLAM PHARMACEUTICALS, INC. (ALNY) Gross margin 2017–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) gross margin by fiscal year — reported gross profit divided by reported revenue.
81.8%FY2025 · since FY2017: 100.0% → 81.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 81.8% | -4.6 pp |
| FY2024 | 86.4% | +1.0 pp |
| FY2023 | 85.3% | -1.2 pp |
| FY2022 | 86.5% | +0.1 pp |
| FY2021 | 86.4% | +1.4 pp |
| FY2020 | 84.9% | -3.6 pp |
| FY2019 | 88.6% | -9.0 pp |
| FY2018 | 97.6% | -2.4 pp |
| FY2017 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →